Sermorelin vs Somatropin (HGH)
A side-by-side research comparison of Sermorelin and Somatropin (HGH) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Sermorelin | Somatropin (HGH) |
|---|---|---|
| Full name | Sermorelin Acetate (GHRH 1-29) | Recombinant Human Growth Hormone |
| Category | Growth Hormone | Growth Hormone |
| Status | Previously FDA-approved (discontinued 2008) | Prescription medication |
| Mechanism | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. | Binds to GH receptors on target cells, triggering the JAK2/STAT5 signaling pathway. Stimulates hepatic IGF-1 production, promotes protein synthesis, mobilizes fatty acids from adipose tissue, and increases glucose output. |
| Molecular weight | 3,358 Da | 22,124 Da |
| Half-life | 10-20 minutes | 2-3 hours (subcutaneous); tissue effects persist 9-17 hours via IGF-1 |
| Bioavailability | Moderate (SubQ) | ~80% subcutaneous |
| Typical dose | 200-300 mcg | 1-4 IU/day (anti-aging/wellness); 4-8 IU/day (performance) |
| Frequency | Once daily before bed | Daily (split AM/PM for higher doses) |
| Route | Subcutaneous injection | Subcutaneous injection |
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Somatropin (HGH) reported benefits
- Fat loss (especially visceral)
- Increased lean muscle mass
- Improved sleep quality
- Faster recovery from injury
- Improved skin elasticity
- Increased bone density
- Enhanced cognitive function
Related comparisons
Research and educational reference only. Not medical advice.